Treating Duchenne muscular dystrophy before symptoms emerge may improve motor function, clinical trial suggests

Researchers at Binghamton University have published Phase II clinical trial data suggesting that early intervention with vamorolone (Agamree) significantly improves motor function in young children with Duchenne muscular dystrophy (DMD). The study focused on steroid-naive boys aged two to four, a younger demographic than typically treated with standard corticosteroids, which often carry severe side effects like growth stunting. These findings are particularly significant for the pharmaceutical sector as DMD was recently added to the U.S. Recommended Universal Screening Panel, potentially opening a market for newborn and presymptomatic treatments.

Vamorolone, marketed as Agamree, was developed by Eric P. Hoffman and Kanneboyina Nagaraju and received FDA approval in 2023 for the treatment of DMD. While previous studies focused on children aged four to seven, this Phase II open-label trial evaluated the drug's efficacy in 20 steroid-naive boys between the ages of two and four. Participants received daily doses of either 2 mg/kg or 6 mg/kg over a 12-week period, with most continuing into a two-year expanded access program. The research aimed to address the progressive nature of DMD, where muscle tissue is gradually replaced by scar tissue, by intervening before significant damage occurs.

The trial results, published in the journal Neurology, demonstrated a rapid improvement in gross motor skills, particularly at the higher dosage. Using the Bayley III scale, researchers observed that DMD patients improved from a baseline score of five to a score of eight out of 10 after 12 weeks of treatment, approaching the score of 10 seen in healthy peers. Crucially, vamorolone appeared to avoid the growth stunting typically associated with traditional corticosteroids like prednisone and deflazacort. However, the drug did not eliminate all side effects; researchers noted instances of weight gain and adrenal suppression, especially in the high-dose group, though no serious adverse events or treatment discontinuations were reported.

The success of this trial highlights a shift toward earlier therapeutic intervention in the DMD market, which is the second-most common genetic disease globally. Vamorolone is already the first drug to receive approval for DMD worldwide, including in the United States, China, the European Union, and the United Kingdom. The recent addition of DMD to the U.S. Recommended Universal Screening Panel (RUSP) for newborns underscores the importance of having safe, effective treatments ready for infants. If these preliminary findings are confirmed in larger, double-blind, placebo-controlled trials, vamorolone could become a primary option for presymptomatic patients, potentially altering the clinical trajectory of the disease.